Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. - Gonzalez-Angulo AM; Lei X; Alvarez RH; Green MC; Murray JL; Valero V; Koenig KB; Ibrahim NK; Litton JK; Nair L; Krishnamurthy S; Hortobagyi GN; et al. (Clinical breast cancer, 2015)